Evidence map›Paper›PMID 33941248›Full record

ArticleArthritis research & therapy2021

Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis.

Yuzuru Yamamoto, Takaichi Okano, Hirotaka Yamada, Kengo Akashi, Sho Sendo, Yo Ueda, Akio Morinobu, Jun Saegusa

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuzuru YamamotoDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Takaichi OkanoDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Hirotaka YamadaDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Kengo AkashiDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Sho SendoDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Yo UedaDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Akio MorinobuDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Jun SaegusaDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan. jsaegusa@med.kobe-u.ac.jp.ORCID 0000-0001-7606-3743
Kobe University · JPKobe University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undetermined, SSc is characterized by fibrosis and proliferative vascular lesions of the skin and internal organs. SSc involves the gastrointestinal tract in more than 90 % of patients. Soluble guanylate cyclase (sGC) stimulator is used to treat pulmonary artery hypertension (PAH) and has been shown to inhibit experimental skin fibrosis.

methodsFemale C57BL/6J mice were treated with BLM or normal saline by subcutaneous implantation of osmotic minipump. These mice were sacrificed on day 28 or day 42. Gastrointestinal pathologies were examined by Masson Trichrome staining. The expression of fibrosis-related genes in gastrointestinal tract was analyzed by real-time PCR, and the levels of collagen in the tissue were measured by Sircol collagen assay. To evaluate peristaltic movement, the small intestinal transport (ITR%) was calculated as [dyeing distance × (duodenum - appendix)] - 1 × 100 (%). We treated BLM-treated mice with sGC stimulator or DMSO orally and analyzed them on day 42.

resultsHistological examination revealed that fibrosis from lamina propria to muscularis mucosa in the esophagus was significantly increased in BLM-treated mice, suggesting that BLM induces esophageal hyperproliferative and prefibrotic response in C57BL/6J mice. In addition, the gene expression levels of Col3a1, CCN2, MMP-2, MMP-9, TIMP-1, and TIMP-2 in the esophagus were significantly increased in BLM-treated mice. More severe hyperproliferative and prefibrotic response was observed in the mice sacrificed on day 42 than the mice sacrificed on day 28. The ITR% was found to be significantly lower in BLM-treated mice, suggesting that gastrointestinal peristaltic movement was reduced in BLM-treated mice. Furthermore, we demonstrated that sGC stimulator treatment significantly reduced hyperproliferative and prefibrotic response of esophagus and intestine in BLM-treated mice, by histological examination and Sircol collagen assay.

conclusionsThese findings suggest that BLM induces gastrointestinal hyperproliferative and prefibrotic response in C57BL/6J mice, and treatment with sGC stimulator improves the BLM-induced gastrointestinal lesion.

Indexed as

Pulmonary FibrosisScleroderma, SystemicAnimalsBleomycinDisease Models, AnimalFemaleFibrosisGastrointestinal TractHumansMiceMice, Inbred C57BLSoluble Guanylyl CyclaseBleomycinSoluble Guanylyl CyclaseGastrointestinal fibrosisSoluble guanylate cyclase stimulatorSystemic sclerosis

Identifiers

PMID33941248
PMCPMC8091711
OpenAlexW3158675910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.